ADARx CEO's trust holds 5.86M company shares
The report lists 5,861,199 common shares held in trust by Li Zhen and spouse, who share voting and dispositive power.
Rhea-AI Filing Summary
ADARx Pharmaceuticals, Inc. President and CEO Li Zhen reports employee stock options exercisable for common stock, with listed exercise prices from $0.24 to $7.05 and expirations from August 19, 2030, through January 27, 2036. The report also lists options held by Li Zhen's spouse and 5,861,199 common shares held by Li Zhen and spouse as trustees of the Titanium Boulder Irrevocable Trust; they share voting and dispositive power over the trust shares.
Insights
Analyzing...
Insider Trade Summary
18 transactions reported
Mixed
18 txns
Insider
Li Zhen
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F3 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F5 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F6 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F7 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F8 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F9 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F10 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F11 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F12 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F13 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F14 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F15 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F16 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F17 | -- | -- | -- |
| holding | Employee Stock Option (right to buy) F18 | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 5,892,514 contracts (Direct);
Employee Stock Option (right to buy) — 68,272 contracts (Indirect, By Spouse);
Common Stock — 5,861,199 shares (Indirect, By Trust)
Footnotes (18)
- F1. The shares are held by the Reporting Person and her spouse as Trustees of the Titanium Boulder Irrevocable Trust dated July 11, 2020 (the "Titanium Trust"). The Reporting Person and her spouse share voting and dispositive power with respect to the securities held by the Titanium Trust.
- F2. Granted to the Reporting Person on August 20, 2020. The shares subject to the option are fully vested and exercisable.
- F3. Granted to the Reporting Person on December 7, 2020. The shares subject to the option are fully vested and exercisable.
- F4. Granted to the Reporting Person on March 19, 2021. The shares subject to the option are fully vested and exercisable.
- F5. Granted to the Reporting Person on May 21, 2021. The shares subject to the option are fully vested and exercisable.
- F6. Granted to the Reporting Person on July 30, 2021. The shares subject to the option are fully vested and exercisable.
- F7. Granted to the Reporting Person on February 23, 2022. The shares subject to the option are fully vested and exercisable.
- F8. Granted to the Reporting Person on February 26, 2023. 1/4 of the total number of shares vested and became exercisable on January 1, 2024 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F9. Granted to the Reporting Person on January 17, 2024. 1/4 of the total number of shares vested and became exercisable on January 1, 2025 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F10. Granted to the Reporting Person on February 12, 2025. 1/4 of the total number of shares vested and became exercisable on January 1, 2026 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F11. Granted to the Reporting Person on January 28, 2026. 1/4 of the total number of shares vest and become exercisable on January 1, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- F12. Granted to the Reporting Person's spouse on August 20, 2020. The shares subject to the option are fully vested and exercisable.
- F13. Granted to the Reporting Person's spouse on March 19, 2021. The shares subject to the option are fully vested and exercisable.
- F14. Granted to the Reporting Person's spouse on February 23, 2022. The shares subject to the option are fully vested and exercisable.
- F15. Granted to the Reporting Person's spouse on February 26, 2023. 1/4 of the total number of shares vested and became exercisable on January 1, 2024 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's spouse's continued service to the Issuer on each vesting date.
- F16. Granted to the Reporting Person's spouse on January 17,2024. 1/4 of the total number of shares vested and became exercisable on January 1, 2025 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's spouse's continued service to the Issuer on each vesting date.
- F17. Granted to the Reporting Person's spouse on February 12, 2025. 1/4 of the total number of shares vested and became exercisable on January 1, 2026 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's spouse's continued service to the Issuer on each vesting date.
- F18. Granted to the Reporting Person's spouse on January 28, 2026. 1/4 of the total number of shares vest and become exercisable on January 1, 2027 and the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to the Reporting Person's spouse's continued service to the Issuer on each vesting date.
Key Figures
Direct employee stock option underlying shares: 1,171,325 shares; $0.24 exercise price
Direct employee stock option underlying shares: 426,730 shares; $7.05 exercise price
Spouse's employee stock option underlying shares: 17,069 shares; $0.24 exercise price
+1 more
4 metrics
Direct employee stock option underlying shares
1,171,325 shares; $0.24 exercise price
Expiration August 19, 2030
Direct employee stock option underlying shares
426,730 shares; $7.05 exercise price
Expiration February 11, 2035
Spouse's employee stock option underlying shares
17,069 shares; $0.24 exercise price
Expiration August 19, 2030
Common shares held by Titanium Boulder Irrevocable Trust
5,861,199 shares
Held by Li Zhen and spouse as trustees
Key Terms
Employee Stock Option (right to buy), fully vested and exercisable, voting and dispositive power, quarterly installments
4 terms
Employee Stock Option (right to buy) technical
"Employee Stock Option (right to buy)"
fully vested and exercisable financial
"shares subject to the option are fully vested and exercisable"
voting and dispositive power regulatory
"share voting and dispositive power with respect to the securities"
quarterly installments financial
"vest and become exercisable in equal quarterly installments"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What options does ADRX CEO Li Zhen report?
Li Zhen reports options exercisable for common stock, including 1,171,325 shares at a $0.24 exercise price expiring August 19, 2030, and 426,730 shares at a $7.05 exercise price expiring February 11, 2035. The report also lists options held by Li Zhen's spouse.
AI-generated analysis. How Rhea-AI works. Not financial advice.
